Tag Archives: Big Pharma

Fred Hassan: More Musings on the Biopharma Learning Curve

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.” In other words, because the circumstances of any setback are unique, the astute manager knows that recovery depends on recognizing that the […]
Posted in healthcare, leadership, People, R&D, Sales, Strategy | Also tagged , , , , | 2 Comments

Storytelling Partnerships – the New Face of Big Pharma Marketing

Doing deals with storytellers could be as important for pharma as collaborating with research scientists, writes Peter Houston. Leading advertising trade publication Ad Week ran an interesting feature on the ‘New Face of Big Pharma Marketing’ this week. The piece outlines the changes that Obamacare combined with public distrust of pharma is forcing on marketers, noting […]
Posted in E-Media, Europe, Guest Blog, Marketing, Op-Ed, Strategy | Also tagged , , , , , | Leave a comment

Teva Joins Top 10, “Face” of Big Pharma Changing

Teva’s accession to the exclusive group that is the Pharma Top 10 is further proof, according to IMS Health, that branded pharma needs to renounce its product-protected past and embrace the patient-led, specialty-focused future. As the first non-western, non-innovative-core company to enter pharma’s global Top 10, according to IMS Health research, Teva’s rise to prominence […]
Posted in Global, Strategy | Also tagged , , | 1 Comment

Merck and Novartis Down in Q3 Financial Reports

By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Posted in Deals, Global, Guest Blog, leadership | Also tagged , , , | Leave a comment

Is the Worst of the Patent Cliff Behind Us?

By Amy Ritter. In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable. The Moody’s rating reflects expectations for fundamental business conditions in the industry over the next 12 to 18 months, and until now, the industry had been limping along under a […]
Posted in Op-Ed | Also tagged , , | 1 Comment
  • Categories

  • Meta